Vericel Corp represents a commitment to improving patients' lives through innovative cell therapy solutions. The company seeks to develop and commercialize therapies that restore or regenerate damaged tissues. Vericel Corp espouses integrity, excellence, and patient focus as its core values. With a passion for scientific advancement and dedication to delivering transformative treatments, Vericel Corp strives to positively impact the lives of patients and healthcare providers. By leveraging cutting-edge research and technology, the company aims to address significant unmet medical needs and improve outcomes in areas such as orthopedic and cardiac care.

Vericel Corp is primarily present in the United States.

Vericel Corp has achieved several significant milestones since its inception. The company has successfully developed and gained FDA approval for two pioneering treatments, MACI and Epicel. MACI is a breakthrough therapy for the repair of adult knee cartilage defects, offering long-lasting pain relief and improved function for patients. On the other hand, Epicel is an advanced treatment for severe burns, providing a permanent solution for covering large burn areas. Vericel Corp has also expanded its presence in the market through strategic collaborations and partnerships, strengthening its position as a leading innovator in the regenerative medicine field.

Vericel Corp, established in 1989, is a leading biopharmaceutical company specializing in the development and commercialization of innovative cell therapies. With headquarters in Cambridge, Massachusetts, Vericel focuses on delivering transformative therapies to patients with serious medical conditions. The company initially operated under the name Aastrom Biosciences and rebranded as Vericel in 2014. Over the years, Vericel Corp has made significant advancements in the field of regenerative medicine, particularly in utilizing a patient's own cells to create personalized therapies. With a strong commitment to research, development, and clinical trials, Vericel continues to make strides in providing groundbreaking treatments to improve patients' lives.

The main competitors of Vericel Corp in the market are companies like NuVasive, Organogenesis Holdings Inc., and Athersys Inc. These companies operate in the same industry and offer similar products and services. However, Vericel Corp differentiates itself through its innovative technologies, strong research and development capabilities, and its focus on regenerative medicine solutions. With its unique product portfolio and market expertise, Vericel Corp remains well-positioned in the market despite competition from these key rivals.

Vericel Corp is primarily active in the biotechnology industry.

The business model of Vericel Corp revolves around the development and commercialization of innovative cell therapy products. Vericel focuses on using advanced cellular and regenerative medicine technologies to provide treatments for patients with severe diseases and conditions. The company's portfolio includes products such as MACI, an autologous cellularized scaffold for the repair of symptomatic, full-thickness cartilage defects of the knee, and Epicel, a permanent skin replacement for patients with deep dermal or full-thickness burns. Vericel Corp aims to address unmet medical needs and improve the lives of patients through its cutting-edge cell therapy solutions.

P/E santykio šiuo metu Vericel apskaičiuoti negalima.

KUV šiuo metu negali būti apskaičiuotas Vericel.

AlleAktien kokybės įvertis Vericel yra 2/10.

Pajamos šiuo metu negali būti apskaičiuotos Vericel.

Pelnas šiuo metu negali būti apskaičiuotas Vericel.

Vericel Corp is a leading biopharmaceutical company specializing in the development, manufacturing, and marketing of products for the regeneration of human tissue. The company focuses on researching and developing top-tier therapeutic options for critical medical needs that have previously been unmet. One important area of the company is the extraction, cultivation, and processing of autologous cells and tissues. Vericel's products are derived from the patient's own tissue, making them particularly safe and suitable for use. The company offers innovative treatment options based on the use of autologous cells and tissues obtained from the skin, bone marrow, adipose tissue, and other tissues. The flagship product, MACI, is a cell transplantation product used to treat knee cartilage damage in adult patients. MACI is unique in that the process of autologous tissue engineering is employed in its production, facilitating the regeneration of the patient's cartilage. Vericel's second area of focus is the treatment of patients with severe burns. This area includes the use of the product Epicel, which is used to treat large burn wounds. Epicel is created by applying an autologous keratinocyte cell suspension film to the wound, resulting in rapid and effective wound healing. Vericel also has an extensive clinical pipeline focused on tissue regeneration and the treatment of degenerative diseases. The company is working on developing autologous cell therapies to improve outcomes for patients with myocardial infarction and various neurological conditions such as ALS, Huntington's disease, and Parkinson's disease. To sustain and expand its business, Vericel collaborates with a variety of partners including hospitals, clinics, and practices. The company also has a strong marketing initiative to raise awareness of its innovative products and their medical benefits. In conclusion, Vericel Corp's business model is based on the development of novel and innovative therapeutic options using autologous cells and tissues. These therapies have great potential to aid patients with previously unmet medical needs. Through a strong marketing initiative, partnerships, and an extensive clinical pipeline, the company strives for steady growth and success.

Vericel moka dividendą 0 USD, kuris yra paskirstytas per išmokas per metus.

Dividenda šiuo metu negali būti apskaičiuota Vericel arba įmonė dividendų nemoka.

Vericel ISIN yra US92346J1088.

Vericel WKN yra A12FU4.

Vericel akcijų simbolis yra VCEL.

Per paskutinius 12 mėnesių Vericel išmokėjo dividendą, kurios dydis siekė . Tai atitinka maždaug dividendų grąžą. Artimiausiems 12 mėnesiams Vericel tikėtina išmokės dividendus, kurie sudarys 0 USD.

Vericel šiuo metu yra dydžio dividendų grąža.

Vericel moka dividendus kas ketvirtį. Jie išmokami mėnesiais.

Vericel per paskutiniuosius 0 metus kiekvienais metais mokėjo dividendus.

Artimiausiems 12 mėnesiams tikimasi dividendų, kurių dydis yra 0 USD. Tai atitinka 0 % dividendų grąžos procentą.

Vericel priskiriamas sektoriui "Sveikata".

Norėdamas gauti paskutinį Vericel dividendą nuo 2024-12-20, kurio dydis yra 0 USD, turėjai turėti akciją savo depozite prieš ex-dieną, kuri buvo 2024-12-20.

Paskutinės dividendų išmokėjimas įvyko 2024-12-20.

2023 metais Vericel išmokėjo 0 USD dividendų.

Vericel dividendai yra mokami USD.